11.05.2017 • NewsElaine BurridgeEuropeUK

EU Approves First Childhood Neuroblastoma Drug

(c) Mark Evans/Getty Images
(c) Mark Evans/Getty Images

UK specialty pharmaceutical company EUSA Pharma has won European approval for its monoclonal antibody dinutuximab beta to treat children over the age of 12 months with neuroblastoma, a rare cancer.

The approval is the first in Europe for high-risk neuroblastoma, which predominantly affects children under five years and spreads very quickly. Around 1,200 children are diagnosed in Europe every year with the disease.

The decision means that the drug can now be made available across Europe, improving access for thousands of children and their families to this new treatment, with proven improved survival rates, noted Steve Richards, CEO of the neuroblastoma charity Solving Kids’ Cancer Europe.

“The next challenge will be for EUSA Pharma to engage with relevant access bodies throughout Europe, including NICE (the UK National Institute for Health and Care Excellence) in the UK, to ensure timely review through the new drugs processes and secure access to this medicine for patients. The young innocent victims of this cruel and devastating disease deserve nothing less,” Richards commented

EUSA, which acquired exclusive global commercialization rights to the drug from Austrian biotech firm Apeiron Biologics in October last year, said it also expects to file for approvals in the US and Japan during 2017.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read